108857-39-2

Basic information

• Product Name: 1-(4-Amino-3-bromo-5-methylphenyl)-2,4-dimethylimidazole
• Synonyms: 1-(4-Amino-3-bromo-5-methylphenyl)-2,4-dimethylimidazole
• CAS NO: 108857-39-2
• Molecular Weight: 280.167
• Mol File: 108857-39-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-(4-Amino-3-bromo-5-methylphenyl)-2,4-dimethylimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-Amino-3-bromo-5-methylphenyl)-2,4-dimethylimidazole(108857-39-2)
• EPA Substance Registry System: 1-(4-Amino-3-bromo-5-methylphenyl)-2,4-dimethylimidazole(108857-39-2)

Safety Data

• Hazardous Substances Data: 108857-39-2(Hazardous Substances Data)

Upstream product

• 102792-03-0 1-(4-Amino-3-methylphenyl)-2,4-dimethylimidazole 
• 102792-10-9 2,4-Dimethyl-1-(3-methyl-4-nitrophenyl)imidazole 
• 446-33-3 5-Fluoro-2-nitrotoluene 
• 930-62-1 2,4-Dimethylimidazole 

Downstream Products

• 108857-38-1 1-(4-amino-3-cyano-5-methylphenyl)-2,4-dimethylimidazole 
• 108857-35-8 1-(4-amino-3-formyl-5-methylphenyl)-2,4-dimethylimidazole 
• 118111-98-1 1-(3-Acetyl-4-amino-5-methylphenyl)-2,4-dimethylimidazole 
• 118111-97-0 1-(4-Acetamido-3-acetyl-5-methylphenyl)-2,4-dimethylimidazole 
• 121375-11-9 ethyl N-<(2-amino-5-(2,4-dimethylimidazol-1-yl)-3-methylphenyl)methyl>glycinate 
• 108857-36-9 2-[2-Amino-5-(2,4-dimethyl-imidazol-1-yl)-3-methyl-benzylamino]-propionic acid ethyl ester 
• 121375-16-4 {[1-[2-Amino-5-(2,4-dimethyl-imidazol-1-yl)-3-methyl-phenyl]-meth-(E)-ylidene]-amino}-acetic acid ethyl ester 
• 108857-37-0 2-[2-Amino-5-(2,4-dimethyl-imidazol-1-yl)-3-methyl-benzylamino]-2-methyl-propionic acid methyl ester 
• 108857-20-1 ethyl N-cyano-N-<<2-amino-3-methyl-5-(2,4-dimethylimidazol-1-yl)phenyl>methyl>glycinate 

Relevant articles and documents

2(1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five membered heteroaryl) derivatives

A series of 6-(N-linked, five membered heteroaryl)-2(1H)-quinolinone derivatives was synthesized and evaluated for cardiotonic activity. Most compounds were prepared by sulfuric acid catalyzed cyclization of an N-(4-heteroarylphenyl)-3-ethoxypropenamide o

Tetrahydroimidazoquinazolinone inotropic agents

A series of novel heterocyclic-substituted 1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one compounds have been prepared, including their pharmaceutically acceptable salts, wherein the heterocyclic ring moiety is an optionally substituted 5- or 6-membered aromatic heterocyclic group attached to the 6-, 7-, 8- or 9-positions of the aforesaid tetrahydroquinaxolinone ring. These particular compounds are useful in therapy as highly potent inotropic and therefore, are of value in the treatment of various cardiac conditions. Preferred member compounds include 7-(2,4-dimethylimidaxol-1-yl)-9-methyl-1,2,4,5,-tetrahydroimidazo (2,1-b)quinazolin-2-(1H)-one, 3,9-dimethyl-7-(2,4-dimethylimidazol-1-yl) -1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one and 9-methyl-7 -(1,2,4-triazol-4-yl)-1,2,3,5-tetrahydroimidazo(2,1-b)quinazolin-2-(1H)-one, respectively. Methods for preparing these compounds from known starting materials are provided.